人源抗SARS病毒噬菌体抗体库的构建及筛选

目的: 构建人源抗SARS病毒的Fab片段抗体基因的噬菌体表面呈现文库, 筛选抗SARS病毒特异性的噬菌体抗体。方法: 用PCR扩增人Fab片段抗体基因, 连入载体pComb3内, 构建噬菌体抗体库。以固相化的SARS抗原淘筛抗体库, 并用ELISA检测噬菌体抗体结合SARS病毒的特异性。结果: 用PCR共扩增出 13条Ig基因片段。电转化构建的噬菌体抗体库的库容为 1. 3×106, Fab基因的重组率为60%。以纯化的SARS抗原淘筛 3轮, 特异性富集了抗SARS病毒的噬菌体抗体, 并用ELISA法从中筛选出了 10个结合活性好、特异性强的克隆。结论: 成功地构建了人源抗SARS病毒的组合抗体文库, 从中获得人源抗SARS病毒的特异性抗体。     

抗人巨细胞病毒中和性人源基因工程抗体的研究

目的 研究抗人巨细胞病毒(HCMV)人源基因工程抗体。方法 采用噬菌体表面展示技术。首先从HCMV感染者外周血中分离淋巴细胞，提取RNA，逆转录后用特异性引物扩增轻、重链基因。然后插入噬菌体载体pComb3，构建噬菌体抗体库。使用纯化的HCMV病毒裂解物对噬菌体抗体库进行4轮富集，然后通过ELISA筛选阳性克隆，并对获得的克隆进行功能鉴定。结果 克隆和表达了3株抗HCMV人源Fab抗体，经ELISA证明均具有抗原结合活性，间接免疫荧光试验证明具有较高的特异性，最后通过病毒中和试验证明其中2株具有中和活性。结论 获得2株抗HCMV人源Fab抗体，具有一定的中和活性，为下一步研究抗HCMV人源全抗体奠定了基础。     

从半合成噬菌体抗体库中克隆抗地高辛人单链抗体1

目的从半合成噬菌体抗体库中克隆抗地高辛(Dig)人单链抗体(ADAScFv),为Dig中毒的诊断和治疗提供人源性抗体.方法1以改良法制备Dig-BSA偶联物;2以固相化的Dig-BSA偶联物对人噬菌体ScFv抗体库进行了4轮筛选,通过ELISA筛选出能结合Dig的抗体克隆并鉴定其活性,通过ELISA竞争抑制实验分析其特异性,对阳性克隆的DNA进行测序分析.结果1在对抗体库的筛选过程中可见有明显的富集;2获得一株可结合Dig及其类似物的阳性克隆;3阳性克隆的可变区分别属于VH5和Vλ1亚群.结论利用噬菌体抗体库技术获得了能与Dig及其它洋地黄类药物结合的人ADAScFv,经进一步分析及抗体工程改造后,有可能为临床上诊断及治疗洋地黄类药物中毒提供具有实用价值的人源性抗体.     

应用噬菌体随机肽库技术筛选SARS-CoV S蛋白模拟表位

目的筛选SARS病毒(Severe acutere spiratorysyndromeas sociated coronavirus,SARSCoV)结构蛋白S(Spike)特异性的模拟表位,为抗SARS疫苗研究提供基础。方法以抗SARS病毒S蛋白的单克隆抗体为固相筛选分子,对人工合成的噬菌体随机12肽库进行5轮“吸附洗脱扩增”的筛选,随机挑选30个克隆,经噬菌体酶联免疫吸附(ELISA)法和交叉反应实验鉴定阳性克隆,再进行DNA序列分析和竞争抑制结合实验,以确定SARS病毒S蛋白的模拟表位。结果经噬菌体富集后,从随机挑选的30个克隆中得到了29个编码8种12肽的阳性克隆,8条肽与S蛋白的320～350氨基酸序列有较高同源性,确定YF、W、E和K氨基酸残基为模拟表位的骨架结构。结论用噬菌体12肽库成功筛选到了SARS病毒S蛋白的模拟表位,为基于S蛋白的肽疫苗研制提供了基础。     

从半合成噬菌体抗体库中克隆抗地高辛人单链抗体

目的：从半合成噬菌体抗体库中克隆抗地高辛（Dig）人单链抗体（ADA ScFv），为Dig中毒的诊断和治疗提供人源性抗体。方法：①以改良法制备Dig-BSA偶联物②以固相化的Dig-BSA偶联物对人噬菌体ScFv抗体库进行了4轮筛选，通过ELISA筛选出能结合Dig的抗体克隆并鉴定其活性，通过ELIS竞争抑制实验分析其特异性，对阳性克隆的DNA进行测序分析。结果：①在对抗体库的筛选过程中可见有明显的富集；②获得一株可结合Dig及其类似物的阳性克隆；③阳性克隆的可变区分别属于VH5和Vλ1亚群。结论：利用噬菌体抗体库技术获得了能与Dig及其它洋地黄类药物结合的人ADA ScFv，经过一步分析及抗体工程改造后，有可能为临床上诊断及治疗洋地黄类药物中毒提供具有实用价值的人源性抗体。     

人源性bFGF单链抗体的筛选、表达及鉴定

目的 用重组人碱性成纤维细胞生长因子(rhbFGF)筛选大容量人源噬菌体抗体库,获得能与bFGF特异性结合的人源性单链抗体(scFv).方法 用rhbFGF对大容量人源噬菌体抗体库进行4轮"吸附-洗脱-扩增"筛选,并通过phage ELISA法对随机挑选的克隆进行抗原结合活性测定,得到的阳性克隆进一步进行原核可溶性表达及鉴定.结果 从104个随机挑选的克隆中,筛得39株抗bFGF的抗体,通过对抗体可变区基因进行多样性分析,发现存在8种不同抗体可变区基因,挑选其中8株phage ELISA显色最高的克隆进行酶切和测序鉴定,发现其中7株为正确的抗体基因序列,通过大肠杆菌成功的进行了scFv的可溶性表达,通过竞争ELISA发现其中一株scFv能够抑制bFGF与其高亲和力受体FGFR1βⅢC的结合.结论 通过筛选噬菌体抗体库获得到7株抗bFGF特异性抗体,其中一株抗体能够抑制bFGF与其高亲和力受体FGFR1的结合.     

重链可变区基因随机CDR3ScFv噬菌体抗体库的构建及筛选

目的构建VH 基因随机CDR3ScFv噬菌体抗体库 ,并筛选抗HFRS病毒NP抗原的噬菌体抗体。方法采用随机引物PCR法扩增抗HFRS病毒mAb1A8的VH 基因 ,并与1A8VL 基因共同克隆入噬菌粒表达载体 pHEN1后 ,构建VH 基因随机CDR3ScFv基因库。继用辅噬菌体VCSM13超感染后得到噬菌体抗体库 ,然后用HFRS病毒抗原进行筛选。随机挑取筛选的菌落超感染 ,用夹心ELISA检测超感染上清。结果获得库容量约为107 噬菌体抗体库。夹心ELISA的结果表明 ,筛选出的噬菌体抗体可与HFRS病毒NP抗原特异性结合。结论成功地构建了库容量较高的ScFv噬菌体抗体库 ,并获得可与HFRS病毒NP抗原结合的噬菌体抗体。     

从噬菌体抗体库中筛选抗Cry1Ac蛋白单链抗体

目的:从Tomlinson J噬菌体抗体库中筛选人源化抗Cry1Ac蛋白单链抗体(scFv)并进行鉴定.方法:以Cry1Ac蛋白为抗原包被固相,经4轮"吸附-洗脱-扩增"过程后,挑取单克隆,用ELISA法测定特异性结合活性,并对其进行基因序列测定.结果:经过4轮筛选,获得了2株能与Cry1Ac蛋白特异性结合的阳性克隆.结论:利用噬菌体抗体库技术可以不经过免疫制备出高特异性的人源化抗Cry1Ac蛋白scFv,为Cry1Ac毒素蛋白检测提供了条件.     

人噬菌体抗体库的构建和甲肝抗体的筛选

目的　构建人噬菌体抗体组合文库,筛选人单克隆抗体。方法　用RTPCR扩增人全套抗体基因片段,克隆于pComb3载体,电转化E.coli形成噬菌体抗体库;以固相化抗原淘筛抗体库,ELISA鉴定噬菌体抗体。结果　17对免疫球蛋白引物全部能够扩增出目的片段;经数次电转化构建了库容为693×107的抗体库,滴度为8×1014PFU/ml,Fab基因重组率为40%。以单抗捕获的甲肝抗原淘洗3轮,出现特异性富集;阳性克隆经直接ELISA和竞争抑制性ELISA实验证实具有良好的抗甲肝抗原特异性,无交叉反应性。结论　成功构建了抗体组合文库,从中获得抗甲肝抗原的特异性人抗体。     

抗戊型肝炎病毒噬菌体抗体库的构建与筛选

目的 :构建人抗戊型肝炎病毒 (HEV)噬菌体抗体库 ,筛选人源中和性抗HEV的单克隆抗体 (mAb)。方法 :取抗HEV抗体阳性的 6例HE患者静脉血 ,分离淋巴细胞 ,提取细胞总RNA后逆转录。用一组人IgGFab基因特异性引物 ,分别扩增IgGκ0轻链与重链Fd段基因。将κ轻链与Fd段基因先后克隆入噬菌体载体pComb3的相应位点 ,经电穿孔法转化大肠杆菌XL1 Blue ,再以辅助噬菌体VCSM13超感染 ,构建人抗HEV噬菌体抗体库。采用独特的 5轮筛选法 (逐渐降低抗原包被量 ,严格洗脱条件 ) ,以固相化的 4种含中和抗原表位的HEV代表株ORF2重组混合抗原 ,筛选人噬菌体抗体库 ,并以ELISA鉴定噬菌体抗体。结果 :经数次电转化构建了容量为1.9× 10 7重组率为 80 %的κ轻链基因库 ;容量为 1.8× 10 7重组率为 2 0 %的Fab基因库。以含中和抗原表位的HEV代表株ORF2重组混合抗原特异淘筛 5次 ,出现特异富集。ELISA鉴定第 5轮筛选产物 ,得到 4株与HEVORF2重组混合抗原具有较高亲和力的Fab噬菌体抗体 ,可能为中和抗体。结论 :成功地构建了人抗HEV噬菌体抗体库 ,并获得人源抗HEV特异性噬菌体抗体。     

从噬菌体抗体库筛选获得中和性人源抗甲型肝炎病毒Fab抗体

目的 研究人源抗甲型肝炎病毒基因工程抗体,为预防甲型肝炎病毒感染提供有效的方法。方法 采用噬菌体表面展示技术,从一名甲型肝炎恢复期病人的抗凝血中分离淋巴细胞,提取总ＲＮＡ逆转录后,用一组人ＩｇＧ Ｆａｂ特异性引物扩增。结果 克隆和表达了８株人源抗甲型肝炎病毒抗体Ｆａｂ段基因,经ＥＬＩＳＡ检测为特异性人抗甲型肝炎病毒Ｆａｂ段抗体。结论 该８株人源抗甲型肝炎病毒Ｆａｂ抗体都能与具有中和活性的鼠抗甲型肝炎病毒单克隆抗体产生竞争抑制反应,选其中的２株做体外中和实验,证明都有中和甲型肝炎病毒的活性。     

Production of an anti-severe acute respiratory syndrome (SARS) coronavirus human monoclonal antibody Fab fragment by using a combinatorial immunoglobulin gene library derived from patients who recovered from SARS

A combinatorial human immunoglobulin gene library was constructed from the peripheral lymphocytes of two patients who recovered from severe acute respiratory syndrome (SARS). The library was screened for the production of Fab antibody fragments to a recombinant spike protein of SARS-associated coronavirus (SARS-CoV). One Fab clone, AS3-3, reacted with the spike protein in an enzyme-linked immunosorbent assay. The dissociation constant of AS3-3 was 1.98 x 10(-8) M. Immunofluorescent microscopy revealed that it reacted with SARS-CoV-infected cells. The library seems to be a potent tool for the production of human antibodies to SARS-CoV.     

Isolation of therapeutic human monoclonal antibodies for varicella-zoster virus and the effect of light chains on the neutralizing activity

Therapeutic antibodies against varicella-zoster virus (VZV) were isolated from a combinatorial library of human antibodies using a phage-display system. Purified gH:gL was used to screen the library, and approximately 300 clones were isolated. Eight kinds of Fab-cp3-fused molecules (clones 10, 24, 36, 60, 94, 120, 192, and 431) neutralized viral infectivity. After conversion of Fab-cp3 antibodies to the Fab-protein A form, the concentrations of antibodies showing 50% inhibition of plaque formation ranged from 0.12 to 400 nM. Clones 10, 24, 94, 120 and 431 neutralized wild strains without showing strain specificity and were further converted to human IgG(1). Two clones (24 and 94) were confirmed to react with gH:gL and VZV-infected cells. IgG of clone 94 prevented spreading of infected cells. Thus these antibodies exhibited the typical phenotype of anti-gH antibody. Next the contribution of light (L) chains to neutralizing activity was analyzed by comparing the effect of L chain of clones 10, 120, and 192 with the identical heavy chain on their neutralizing activity. The L chain in the Fab form of clone 94 was replaced by L chains of clones 10, 24, 36, and 60 and the neutralizing activity of these replaced antibodies was weaker than that of the prototype clone 94. When the kappa-L chain of clone 94 was replaced by the lambda-L chain of clone 24, this antibody possessed neutralizing activity despite the kappa-lambda class change. Thus, human antibody library against VZV-gH has been established and characterized the role of the L chain in VZV-neutralizing activity to engineering further an antibody with stronger neutralizing activity.     

人源抗人免疫缺陷病毒1型噬菌体抗体库的构建及筛选

目的构建人免疫缺陷病毒１型（ＨＩＶ－１）特异性噬菌体抗体库，制备人源抗ＨＩＶ－１ｇｐ１２０单克隆抗体。方法以半巢式聚合酶链反应（ＰＣＲ）从ＨＩＶ－１感染者外周血单个核淋巴细胞中扩增抗体重链Ｆｄ和轻链（ｋ）基因，与噬菌体载体ｐＣｏｍｂ３连接，构建噬菌体抗体Ｆａｂ组合文库。对抗体库进行３轮吸附－洗脱－扩增的亲和选择后，以ＥＬＩＳＡ法筛选抗ＨＩＶ－１ｇｐ１２０噬菌体抗体，并进行ＤＮＡ序列分析和Ｆａｂ的可溶性表达。结果半巢式ＰＣＲ有效地扩增出Ｆｄ和ｋ基因，以此构建成容量为１９５×１０７的噬菌体抗体库。３轮亲和选择使特异性抗体得到高度富集，抗ＨＩＶ－１ｇｐ１２０噬菌体抗体阳性克隆占３２％。对一阳性克隆抗体基因ＣＨ１和ＣＬ部分ＤＮＡ序列进行了测定，并在大肠杆菌表达出可溶性Ｆａｂ。结论抗ＨＩＶ－１特异性噬菌体抗体库的构建和人源抗ＨＩＶ－１ｇｐ１２０单克隆抗体的制备为今后筛选抗ＨＩＶ中和抗体奠定了基础，具有重要的应用价值。     

胰淀素Fab抗体的筛选及初步鉴定

目的:从人天然Fab噬菌体抗体库中筛选胰淀素(amylin又称为胰岛淀粉样多肽)Fab抗体,测定其特异性及抗原结合活性.方法:以胰淀素为抗原,对抗体库进行5轮"吸附-洗脱-扩增"的富集筛选;将从人源噬菌体抗体库中筛选出的阳性克隆,提取其质粒、切除gⅢ、自身环化并转入大肠杆菌中,以IPTG诱导表达可溶性抗体,最后用SDS-PAGE鉴定抗体表达情况、ELISA鉴定抗原结合活性和特异性.结果:成功筛选并表达了抗胰淀素的可溶性Fab抗体,经SDS-PAGE蛋白电泳,在相对分子质量约为47 kD处可见一蛋白条带.ELISA和Western blot证实了该Fab片段与胰淀素抗原的结合活性和特异性.结论:利用噬菌体抗体库技术获得了人源性的特异抗胰淀素Fab抗体,为临床进行下一步研究奠定了基础.     

Cloning and expression of two human recombinant monoclonal Fab fragments specific for EBV viral capsid antigen

Serum titers of antibody to Epstein-Barr virus (EBV) viral capsid antigen (VCA) have been positively correlated with malignancies of lymphoid proliferation, such as Burkitt's lymphoma and Hodgkin's lymphoma. We have constructed a phage display combinatorial antibody Fab library from a patient with marginal zone B cell lymphoma associated with Sj?gren's syndrome and carrying high serum anti-EBV-VCA IgG titer. Fab fragments were selected by panning against EBV-VCA protein coated onto ELISA plates, and selected Fab clones were characterized by ELISA, western blotting (WB), indirect immunofluorescence assay and immunohistochemistry. We have established two Fab clones, Fab-aVCA1 and Fab-aVCA21, which specifically recognize EBV-VCA by ELISA and WB. Inhibition ELISA competition showed that both clones could significantly reduce the binding of specific anti-EBV-VCA mAb to its relevant proteins. Furthermore, these two Fab clones could localize VCA protein in the EBV-positive P3HR1 and Daudi cell lines, as well as in tissue samples from patients with EBV-infected lymphoid malignancies. These results indicate that our two Fab clones are novel human mAbs specific for EBV-VCA protein and may have potential benefits for development of novel diagnostic and therapeutic approaches in EBV-related lymphoid malignancies.     

人源抗乙肝表面抗原基因工程抗体的研究

目的 研制人源抗乙肝表面抗原(HBsAg)基因工程抗体.方法 采集多个HBsAg加强免疫后表面抗体阳性(HBsAb+)志愿者的外周血,分离淋巴细胞,构建人源抗HBsAg Fab噬菌体抗体基因文库.用纯化的HBsAg对抗体库进行富集筛选,经过序列测定确定抗体轻重链型别,分别克隆入真核细胞表达载体pAc-FcR和HL51-14,转染昆虫Sf9细胞和293T细胞,利用杆状病毒/昆虫细胞系统和哺乳动物细胞系统实现全抗体的分泌型表达.结果 成功筛选出20株抗HBsAg的人源Fab抗体并制备出其中6株的IgG全抗体,竞争性ELISA结果显示6株全抗体针对的是HBsAg 3个不同表位.结论 成功筛选并获得了6株针对3个不同表位的抗HBsAg的IgG全抗体,为治疗性抗体和新疫苗的研制奠定了基础.     

Production of a monoclonal antibody against SARS-CoV spike protein with single intrasplenic immunization of plasmid DNA

Severe acute respiratory syndrome (SARS) is a highly infectious disease caused by a novel coronavirus (SARS-CoV). Specific monoclonal antibodies (mAbs) against the SARS-CoV are vital for early diagnosis and pathological studies of SARS. Direct intrasplenic inoculation of plasmid DNA encoding antigen is an effective and fast approach to generate specific mAb when the protein antigen is difficult to prepare or dangerous in use. In this study, we selected one fragment of SARS-CoV spike protein (S1-₃) as antigenic determinant by immunoinformatics. Single intrasplenic immunization of plasmid DNA encoding S1-₃ induced anti-spike protein antibodies. We established one hybridoma cell line secreting specific mAb and evaluated this mAb with murine leukemia virus pseudotyped with SARS-CoV spike protein (MLV/SARS-CoV). The mAb could recognize the spike protein on the MLV/SARS-CoV-infected Vero E6 cells albeit with no neutralizing effect on the infectivity of the pseudotype virus. Our results show that a single-shot intrasplenic DNA immunization is efficient for the production of specific mAb against SARS spike protein, and a linear epitope of the spike protein is recognized in this study.